Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?

References

• Susilo R, Rommelspacher H. Formation of a β-carboline (1,2,3,4-tetrahydro-1-methyl-β-carboline-1-carboxylic acid) following intracerebroventricular injection of tryptamine and pyruvic acid. Naunyn Schmiedebergs Arch. Pharmacol.335, 70–76 (1987).
   PubMedGoogle Scholar
• Herraiz T, Galisteo J. Tetrahydro-β-carboline alkaloids occur in fruits and fruit juices. Activity as antioxidants and radical scavengers. J. Agric. Food Chem.51, 7156–7161 (2003).
   PubMed Web of Science ®Google Scholar
• Gross GA, Turesky RJ, Fay LB, Stillwell WG, Skipper PL, Tannenbaum SR. Heterocyclic aromatic amine formation in grilled bacon, beef and fish and in grill scrapings. Carcinogenesis14, 2313–2318 (1993).
   PubMed Web of Science ®Google Scholar
• Herraiz T, Chaparro C. Analysis of monoamine oxidase enzymatic activity by reversed-phase high performance liquid chromatography and inhibition by β-carboline alkaloids occurring in foods and plants. J. Chromatogr. A.1120, 237–243 (2006).
   PubMedGoogle Scholar
• Liao GZ, Wang GY, Xu XL, Zhou GH. Effect of cooking methods on the formation of heterocyclic aromatic amines in chicken and duck breast. Meat Sci.85, 149–154 (2010).
   PubMed Web of Science ®Google Scholar
• Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun.326, 378–386 (2005).
   PubMed Web of Science ®Google Scholar
• Honecker H, Coper H, Fahndrich C, Rommelspacher H. Identification of tetrahydronorharmane (tetrahydro-β-carboline) in human blood platelets. J. Clin. Chem. Clin. Biochem.18, 133–135 (1980).
   PubMedGoogle Scholar
• Adachi J, Mizoi Y, Naito T, Ogawa Y, Uetani Y, Ninomiya I. Identification of tetrahydro-β-carboline-3-carboxylic acid in foodstuffs, human urine and human milk. J. Nutr.121, 646–652 (1991).
   PubMed Web of Science ®Google Scholar
• Matsubara K, Kobayashi S, Kobayashi Y et al. β-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson’s disease. Neurology45, 2240–2245 (1995).
   PubMed Web of Science ®Google Scholar
• Herraiz T, Guillen H, Aran VJ. Oxidative metabolism of the bioactive and naturally occurring β-carboline alkaloids, norharman and harman, by human cytochrome P450 enzymes. Chem. Res. Toxicol.21(11), 2172–2189 (2008).
   PubMed Web of Science ®Google Scholar
• Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson’s disease. Neurology66, S24–S36 (2006).
   PubMed Web of Science ®Google Scholar
• Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp. Mol. Med.38, 333–347 (2006).
   PubMed Web of Science ®Google Scholar
• Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration. J. Neurosci.28, 7687–7698 (2008).
   PubMed Web of Science ®Google Scholar
• Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J. Neural Transm.117, 971–979 (2010).
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology38, 1285–1291 (1988).
   PubMed Web of Science ®Google Scholar
• Mastroeni D, Grover A, Leonard B et al. Microglial responses to dopamine in a cell culture model of Parkinson’s disease. Neurobiol. Aging30, 1805–1817 (2009).
   PubMedGoogle Scholar
• Gerhard A, Pavese N, Hotton G et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol. Dis.21, 404–412 (2006).
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Yoshikawa E, Sekine Y et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann. Neurol.57, 168–175 (2005).
   PubMed Web of Science ®Google Scholar
• Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol. Scand.100, 34–41 (1999).
   PubMed Web of Science ®Google Scholar
• Neafsey EJ, Albores R, Gearhart D et al. Methyl-β-carbolinium analogs of MPP+ cause nigrostriatal toxicity after substantia nigra injections in rats. Brain Res.675, 279–288 (1995).
   PubMed Web of Science ®Google Scholar
• Ostergren A, Fredriksson A, Brittebo EB. Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra. J. Neural Transm.113, 313–329 (2006).
   PubMedGoogle Scholar
• Polanski W, Enzensperger C, Reichmann H, Gille G. The exceptional properties of 9-methyl-β-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. J. Neurochem.113, 1659–1675 (2010).
   PubMedGoogle Scholar
• Hamann J, Rommelspacher H, Storch A, Reichmann H, Gille G. Neurotoxic mechanisms of 2,9-dimethyl-β-carbolinium ion in primary dopaminergic culture. J. Neurochem.98, 1185–1199 (2006).
   PubMed Web of Science ®Google Scholar
• Hans G, Malgrange B, Lallemend F et al. β-carbolines induce apoptosis in cultured cerebellar granule neurons via the mitochondrial pathway. Neuropharmacology48, 105–117 (2005).
   PubMedGoogle Scholar
• Funayama Y, Nishio K, Wakabayashi K et al. Effects of β- and γ-carboline derivatives of DNA topoisomerase activities. Mutat. Res.349, 183–191 (1996).
   PubMed Web of Science ®Google Scholar
• Collins MA, Neafsey EJ, Matsubara K, Cobuzzi RJ, Jr, Rollema H. Indole-N-methylated β-carbolinium ions as potential brain-bioactivated neurotoxins. Brain Res.570, 154–160 (1992).
   PubMed Web of Science ®Google Scholar
• Matsubara K, Collins MA, Akane A et al. Potential bioactivated neurotoxicants, N-methylated β-carbolinium ions, are present in human brain. Brain Res.610, 90–96 (1993).
   PubMed Web of Science ®Google Scholar
• Kuhn W, Muller T, Grosse H, Rommelspacher H. Elevated levels of harman and norharman in cerebrospinal fluid of Parkinsonian patients. J. Neural Transm.103, 1435–1440 (1996).
   PubMed Web of Science ®Google Scholar
• Gearhart DA, Collins MA, Lee JM, Neafsey EJ. Increased β-carboline 9N-methyltransferase activity in the frontal cortex in Parkinson’s disease. Neurobiol. Dis.7, 201–211 (2000).
   PubMed Web of Science ®Google Scholar
• Stephens DN, Schneider HH, Kehr W, Jensen LH, Petersen E, Honore T. Modulation of anxiety by β-carbolines and other benzodiazepine receptor ligands: relationship of pharmacological to biochemical measures of efficacy. Brain Res. Bull.19, 309–318 (1987).
   PubMedGoogle Scholar
• Aricioglu F, Altunbas H. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann. NY Acad. Sci.1009, 196–201 (2003).
   PubMed Web of Science ®Google Scholar
• Farzin D, Mansouri N. Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test. Eur. Neuropsychopharmacol.16, 324–328 (2006).
   PubMed Web of Science ®Google Scholar
• Aricioglu F, Yillar O, Korcegez E, Berkman K. Effect of harmane on the convulsive threshold in epilepsy models in mice. Ann. NY Acad. Sci.1009, 190–195 (2003).
   PubMedGoogle Scholar
• Husbands SM, Glennon RA, Gorgerat S et al. β-carboline binding to imidazoline receptors. Drug Alcohol Depend.64, 203–208 (2001).
   PubMed Web of Science ®Google Scholar
• Robinson ES, Anderson NJ, Crosby J, Nutt DJ, Hudson AL. Endogenous β-carbolines as clonidine-displacing substances. Ann. NY Acad. Sci.1009, 157–166 (2003).
   PubMed Web of Science ®Google Scholar
• Musgrave IF, Badoer E. Harmane produces hypotension following microinjection into the RVLM: possible role of I(1)-imidazoline receptors. Br. J. Pharmacol.129, 1057–1059 (2000).
   PubMed Web of Science ®Google Scholar
• Sanchez-Blazquez P, Boronat MA, Olmos G, Garcia-Sevilla JA, Garzon J. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br. J. Pharmacol.130, 146–152 (2000).
   PubMed Web of Science ®Google Scholar
• Aricioglu F, Korcegez E, Ozyalcin S. Effect of harmane on mononeuropathic pain in rats. Ann. NY Acad. Sci.1009, 180–184 (2003).
   PubMedGoogle Scholar
• Cao R, Chen Q, Hou X et al. Synthesis, acute toxicities, and antitumor effects of novel 9-substituted β-carboline derivatives. Bioorg. Med. Chem.12, 4613–4623 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar R, Gupta L, Pal P et al. Synthesis and cytotoxicity evaluation of (tetrahydro-β-carboline)-1,3,5-triazine hybrids as anticancer agents. Eur. J. Med. Chem.45, 2265–2276 (2010).
   PubMed Web of Science ®Google Scholar
• Formagio AS, Tonin LT, Foglio MA et al. Synthesis and antitumoral activity of novel 3-(2-substituted-1,3,4-oxadiazol-5-yl) and 3-(5-substituted-1,2,4-triazol-3-yl) β-carboline derivatives. Bioorg. Med. Chem.16, 9660–9667 (2008).
   PubMed Web of Science ®Google Scholar
• Chen X, Cromer BA, Lynch JW. Molecular determinants of β-carboline inhibition of the glycine receptor. J. Neurochem.110, 1685–1694 (2009).
   PubMedGoogle Scholar
• Touiki K, Rat P, Molimard R, Chait A, de Beaurepaire R. Harmane inhibits serotonergic dorsal raphe neurons in the rat. Psychopharmacology (Berl.)182, 562–569 (2005).
   PubMed Web of Science ®Google Scholar
• Yang YJ, Lee JJ, Jin CM, Lim SC, Lee MK. Effects of harman and norharman on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. Eur. J. Pharmacol.587, 57–64 (2008).
   PubMed Web of Science ®Google Scholar
• Wernicke C, Schott Y, Enzensperger C, Schulze G, Lehmann J, Rommelspacher H. Cytotoxicity of β-carbolines in dopamine transporter expressing cells: structure-activity relationships. Biochem. Pharmacol.74, 1065–1077 (2007).
   PubMed Web of Science ®Google Scholar
• Storch A, Hwang YI, Gearhart DA et al. Dopamine transporter-mediated cytotoxicity of β-carbolinium derivatives related to Parkinson’s disease: relationship to transporter-dependent uptake. J. Neurochem.89, 685–694 (2004).
   PubMed Web of Science ®Google Scholar
• Ho BT, McIsaac WM, Tansey LW, Walker KE. Inhibitors of monoamine oxidase. 3. 9-substituted-β-carbolines. J. Pharm. Sci.58, 219–221 (1969).
   PubMedGoogle Scholar
• Rommelspacher H, Meier-Henco M, Smolka M, Kloft C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur. J. Pharmacol.441, 115–125 (2002).
   PubMed Web of Science ®Google Scholar
• Rook Y, Schmidtke KU, Gaube F et al. Bivalent β-carbolines as potential multitarget anti-Alzheimer agents. J. Med. Chem.53(9), 3611–3617 (2010).
   PubMed Web of Science ®Google Scholar
• Rommelspacher H, May T, Susilo R. β-carbolines and tetrahydroisoquinolines: detection and function in mammals. Planta Med.57, S85–S92 (1991).
   PubMed Web of Science ®Google Scholar
• Musshoff F, Daldrup T, Bonte W, Leitner A, Lesch OM. Formaldehyde-derived tetrahydroisoquinolines and tetrahydro-β-carbolines in human urine. J. Chromatogr. B Biomed. Appl.683, 163–176 (1996).
   PubMedGoogle Scholar
• McNaught KS, Carrupt PA, Altomare C et al. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson’s disease. Biochem. Pharmacol.56, 921–933 (1998).
   PubMedGoogle Scholar
• Okuda K, Kotake Y, Ohta S. Neuroprotective or neurotoxic activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline and related compounds. Bioorg. Med. Chem. Lett.13, 2853–2855 (2003).
   PubMedGoogle Scholar
• McNaught KS, Thull U, Carrupt PA et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem. Pharmacol.50, 1903–1911 (1995).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Fukuhara K, Tada-Oikawa S et al. The mechanisms of oxidative DNA damage and apoptosis induced by norsalsolinol, an endogenous tetrahydroisoquinoline derivative associated with Parkinson’s disease. J. Neurochem.108, 397–407 (2009).
   PubMedGoogle Scholar
• Storch A, Ott S, Hwang YI, Ortmann R et al. Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson’s disease: studies using heterologous expression systems of the dopamine transporter. Biochem. Pharmacol.63, 909–920 (2002).
   PubMed Web of Science ®Google Scholar
• Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a Parkinsonism-inducing agent: a novel endogenous amine in mouse brain and Parkinsonian CSF. J. Neurochem.65, 2633–2638 (1995).
   PubMed Web of Science ®Google Scholar
• Lorenc-Koci E, Smialowska M, Antkiewicz-Michaluk L, Golembiowska K, Bajkowska M, Wolfarth S. Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats. Neuroscience95, 1049–1059 (2000).
   PubMedGoogle Scholar
• Okuda K, Kotake Y, Ohta S. Parkinsonism-preventing activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo. Biol. Pharm. Bull.29, 1401–1403 (2006).
   PubMedGoogle Scholar
• Yamakawa T, Ohta S. Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci. Lett.259, 157–160 (1999).
   PubMedGoogle Scholar
• Hamann J, Wernicke C, Lehmann J, Reichmann H, Rommelspacher H, Gille G. 9-methyl-β-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. Neurochem. Int.52, 688–700 (2008).
   PubMed Web of Science ®Google Scholar
• Matsubara K, Gonda T, Sawada H et al. Endogenously occurring β-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson’s disease. J. Neurochem.70, 727–735 (1998).
   PubMed Web of Science ®Google Scholar
• Wernicke C, Hellmann J, Zieba B et al. 9-methyl-β-carboline has restorative effects in an animal model of Parkinson’s disease. Pharmacol. Rep.62, 35–53 (2010).
   PubMed Web of Science ®Google Scholar
• Greffard S, Verny M, Bonnet AM et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol.63, 584–588 (2006).
   PubMed Web of Science ®Google Scholar
• Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm.38, 277–301 (1976).
   PubMed Web of Science ®Google Scholar
• Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson’s disease: role of aging. Ann. Neurol.26, 551–557 (1989).
   PubMed Web of Science ®Google Scholar
• Ugrumov MV. Non-dopaminergic neurons partly expressing dopaminergic phenotype: distribution in the brain, development and functional significance. J. Chem. Neuroanat.38, 241–256 (2009).
   PubMedGoogle Scholar
• Kitahama K, Sakamoto N, Jouvet A, Nagatsu I, Pearson J. Dopamine-β-hydroxylase and tyrosine hydroxylase immunoreactive neurons in the human brainstem. J. Chem. Neuroanat.10, 137–146 (1996).
   PubMedGoogle Scholar
• Ikemoto K, Nagatsu I, Nishimura A, Nishi K, Arai R. Do all of human midbrain tyrosine hydroxylase neurons synthesize dopamine? Brain Res.805, 255–258 (1998).
   PubMedGoogle Scholar
• Ershov PV, Ugrumov MV, Calas A, Krieger M, Thibault J. Differentiation of tyrosine hydroxylase-synthesizing and/or aromatic L-amino acid decarboxylase-synthesizing neurons in the rat mediobasal hypothalamus: quantitative double-immunofluorescence study. J. Comp. Neurol.446, 114–122 (2002).
   PubMedGoogle Scholar
• Hynes M, Porter JA, Chiang C et al. Induction of midbrain dopaminergic neurons by Sonic hedgehog. Neuron15, 35–44 (1995).
   PubMed Web of Science ®Google Scholar
• Prakash N, Brodski C, Naserke T et al. A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development133, 89–98 (2006).
   PubMed Web of Science ®Google Scholar
• Castelo-Branco G, Wagner J, Rodriguez FJ et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl Acad. Sci. USA100, 12747–12752 (2003).
   PubMed Web of Science ®Google Scholar
• Simon HH, Saueressig H, Wurst W, Goulding MD, O’Leary DD. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci.21, 3126–3134 (2001).
   PubMed Web of Science ®Google Scholar
• Saucedo-Cardenas O, Quintana-Hau JD, Le WD et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl Acad. Sci. USA95, 4013–4018 (1998).
   PubMed Web of Science ®Google Scholar
• Maxwell SL, Ho HY, Kuehner E, Zhao S, Li M. Pitx3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development. Dev. Biol.282, 467–479 (2005).
   PubMed Web of Science ®Google Scholar
• Kadkhodaei B, Ito T, Joodmardi E et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci.29, 15923–15932 (2009).
   PubMed Web of Science ®Google Scholar
• Le W, Pan T, Huang M et al. Decreased Nurr1 gene expression in patients with Parkinson’s disease. J. Neurol. Sci.273, 29–33 (2008).
   PubMed Web of Science ®Google Scholar
• Ghee M, Baker H, Miller JC, Ziff EB. AP-1, CREB and CBP transcription factors differentially regulate the tyrosine hydroxylase gene. Brain Res. Mol. Brain Res.55, 101–114 (1998).
   PubMedGoogle Scholar
• Kim KS, Lee MK, Carroll J, Joh TH. Both the basal and inducible transcription of the tyrosine hydroxylase gene are dependent upon a cAMP response element. J. Biol. Chem.268, 15689–15695 (1993).
   PubMed Web of Science ®Google Scholar
• Lewis-Tuffin LJ, Quinn PG, Chikaraishi DM. Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. Mol. Cell Neurosci.25, 536–547 (2004).
   PubMed Web of Science ®Google Scholar
• Tsarovina K, Pattyn A, Stubbusch J et al. Essential role of GATA transcription factors in sympathetic neuron development. Development131, 4775–4786 (2004).
   PubMedGoogle Scholar
• Hong SJ, Huh Y, Chae H, Hong S, Lardaro T, Kim KS. GATA-3 regulates the transcriptional activity of tyrosine hydroxylase by interacting with CREB. J. Neurochem.98, 773–781 (2006).
   PubMed Web of Science ®Google Scholar
• Kwok RP, Lundblad JR, Chrivia JC et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature370, 223–226 (1994).
   PubMed Web of Science ®Google Scholar
• Jiang H, Liu L, Yang S, Tomomi T, Toru N. CREB-binding proteins (CBP) as a transcriptional coactivator of GATA-2. Sci. China C. Life Sci.51, 191–198 (2008).
   PubMedGoogle Scholar
• Scherzer CR, Grass JA, Liao Z et al. GATA transcription factors directly regulate the Parkinson’s disease-linked gene α-synuclein. Proc. Natl Acad. Sci. USA105, 10907–10912 (2008).
   PubMed Web of Science ®Google Scholar
• Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW. Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem.91, 1025–1043 (2004).
   PubMed Web of Science ®Google Scholar
• Cha-Molstad H, Keller DM, Yochum GS, Impey S, Goodman RH. Cell-type-specific binding of the transcription factor CREB to the cAMP-response element. Proc. Natl Acad. Sci. USA101, 13572–13577 (2004).
   PubMedGoogle Scholar
• Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell. Signal.16, 1211–1227 (2004).
   PubMed Web of Science ®Google Scholar
• Hu SC, Chrivia J, Ghosh A. Regulation of CBP-mediated transcription by neuronal calcium signaling. Neuron22, 799–808 (1999).
   PubMedGoogle Scholar
• Du X, Iacovitti L. Multiple signaling pathways direct the initiation of tyrosine hydroxylase gene expression in cultured brain neurons. Brain Res. Mol. Brain Res.50, 1–8 (1997).
   PubMedGoogle Scholar
• Du X, Iacovitti L. Protein kinase C activators work in synergy with specific growth factors to initiate tyrosine hydroxylase expression in striatal neurons in culture. J. Neurochem.68, 564–569 (1997).
   PubMedGoogle Scholar
• Anastasiadis PZ, Kuhn DM, Blitz J, Imerman BA, Louie MC, Levine RA. Regulation of tyrosine hydroxylase and tetrahydrobiopterin biosynthetic enzymes in PC12 cells by NGF, EGF and IFN-γ. Brain Res.713, 125–133 (1996).
   PubMedGoogle Scholar
• Fuxe K, Tinner B, Zoli M et al. Computer-assisted mapping of basic fibroblast growth factor immunoreactive nerve cell populations in the rat brain. J. Chem. Neuroanat.11, 13–35 (1996).
   PubMedGoogle Scholar
• Ditlevsen DK, Owczarek S, Berezin V, Bock E. Relative role of upstream regulators of Akt, ERK and CREB in NCAM- and FGF2-mediated signalling. Neurochem. Int.53, 137–147 (2008).
   PubMedGoogle Scholar
• Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc. Natl Acad. Sci. USA98, 6074–6079 (2001).
   PubMed Web of Science ®Google Scholar
• Neiiendam JL, Kohler LB, Christensen C et al. An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. J. Neurochem.91, 920–935 (2004).
   PubMedGoogle Scholar
• Mograbi B, Bocciardi R, Bourget I et al. Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: importance for the rescue of neuroectodermic cells. J. Biol. Chem.276, 45307–45319 (2001).
   PubMedGoogle Scholar
• Besset V, Scott RP, Ibanez CF. Signaling complexes and protein–protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J. Biol. Chem.275, 39159–39166 (2000).
   PubMedGoogle Scholar
• Soler RM, Dolcet X, Encinas M, Egea J, Bayascas JR, Comella JX. Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons. J. Neurosci.19, 9160–9169 (1999).
   PubMedGoogle Scholar
• Encinas M, Tansey MG, Tsui-Pierchala BA, Comella JX, Milbrandt J, Johnson EM Jr. c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J. Neurosci.21, 1464–1472 (2001).
   PubMedGoogle Scholar
• Pong K, Xu RY, Baron WF, Louis JC, Beck KD. Inhibition of phosphatidylinositol 3-kinase activity blocks cellular differentiation mediated by glial cell line-derived neurotrophic factor in dopaminergic neurons. J. Neurochem.71, 1912–1919 (1998).
   PubMedGoogle Scholar
• Ries V, Cheng HC, Baohan A et al. Regulation of the postnatal development of dopamine neurons of the substantia nigra in vivo by Akt/protein kinase B. J. Neurochem.110, 23–33 (2009).
   PubMedGoogle Scholar
• Ries V, Henchcliffe C, Kareva T et al. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson’s disease. Proc. Natl Acad. Sci. USA103, 18757–18762 (2006).
   PubMed Web of Science ®Google Scholar
• Maurer JA, Wray S. Neuronal dopamine subpopulations maintained in hypothalamic slice explant cultures exhibit distinct tyrosine hydroxylase mRNA turnover rates. J. Neurosci.17, 4552–4561 (1997).
   PubMedGoogle Scholar
• Chuang D, Zsilla G, Costa E. Turnover rate of tyrosine hydroxylase during trans-synaptic induction. Mol. Pharmacol.11, 784–794 (1975).
   PubMedGoogle Scholar
• Keller S, Reichmann H, Gille G. 9-methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of growth factors by astrocytes. Mov. Disord.25, 619 (2010).
   Google Scholar
• Martinez R, Gomes FC. Neuritogenesis induced by thyroid hormone-treated astrocytes is mediated by epidermal growth factor/mitogen-activated protein kinase-phosphatidylinositol 3-kinase pathways and involves modulation of extracellular matrix proteins. J. Biol. Chem.277, 49311–49318 (2002).
   PubMedGoogle Scholar
• Williams EJ, Walsh FS, Doherty P. Tyrosine kinase inhibitors can differentially inhibit integrin-dependent and CAM-stimulated neurite outgrowth. J. Cell Biol.124, 1029–1037 (1994).
   PubMed Web of Science ®Google Scholar
• Seidenfaden R, Krauter A, Hildebrandt H. The neural cell adhesion molecule NCAM regulates neuritogenesis by multiple mechanisms of interaction. Neurochem. Int.49, 1–11 (2006).
   PubMedGoogle Scholar
• Ditlevsen DK, Povlsen GK, Berezin V, Bock E. NCAM-induced intracellular signaling revisited. J. Neurosci. Res.86, 727–743 (2008).
   PubMed Web of Science ®Google Scholar
• Wang DD, Bordey A. The astrocyte odyssey. Prog. Neurobiol.86, 342–367 (2008).
   PubMed Web of Science ®Google Scholar
• Cao JP, Wang HJ, Yu JK, Yang H, Xiao CH, Gao DS. Involvement of NCAM in the effects of GDNF on the neurite outgrowth in the dopamine neurons. Neurosci. Res.61, 390–397 (2008).
   PubMedGoogle Scholar
• Zihlmann KB, Ducray AD, Schaller B et al. The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons. Brain Res. Bull.68, 42–53 (2005).
   PubMedGoogle Scholar
• Beck KD. Functions of brain-derived neurotrophic factor, insulin-like growth factor-I and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons. Prog. Neurobiol.44, 497–516 (1994).
   PubMedGoogle Scholar
• Hyman C, Juhasz M, Jackson C, Wright P, Ip NY, Lindsay RM. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J. Neurosci.14, 335–347 (1994).
   PubMed Web of Science ®Google Scholar
• Krieglstein K, Strelau J, Schober A, Sullivan A, Unsicker K. TGF-β and the regulation of neuron survival and death. J. Physiol. Paris96, 25–30 (2002).
   PubMed Web of Science ®Google Scholar
• Farkas LM, Dunker N, Roussa E, Unsicker K, Krieglstein K. Transforming growth factor-β(s) are essential for the development of midbrain dopaminergic neurons in vitro and in vivo. J. Neurosci.23, 5178–5186 (2003).
   PubMed Web of Science ®Google Scholar
• Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, Sharon R. α-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic10, 218–234 (2009).
   PubMedGoogle Scholar
• Sidhu A, Wersinger C, Vernier P. α-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson’s disease. FEBS Lett.565, 1–5 (2004).
   PubMedGoogle Scholar
• Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci.22, 3090–3099 (2002).
   PubMed Web of Science ®Google Scholar
• Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of α-synuclein. J. Neurochem.96, 950–959 (2006).
   PubMedGoogle Scholar
• Jensen PJ, Alter BJ, O’Malley KL. α-synuclein protects naive but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity. J. Neurochem.86, 196–209 (2003).
   PubMedGoogle Scholar
• Yuan Y, Sun J, Zhao M, Hu J, Wang X, Du G, Chen NH. Overexpression of α-synuclein down-regulates BDNF expression. Cell Mol. Neurobiol.30(6), 939–946 (2010).
   PubMedGoogle Scholar
• Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol.67, 1149–1158 (2008).
   PubMed Web of Science ®Google Scholar
• Vekrellis K, Xilouri M, Emmanouilidou E, Stefanis L. Inducible over-expression of wild type α-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. J. Neurochem.109, 1348–1362 (2009).
   PubMedGoogle Scholar
• MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron52, 587–593 (2006).
   PubMed Web of Science ®Google Scholar
• Imai Y, Gehrke S, Wang HQ et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J.27, 2432–2443 (2008).
   PubMed Web of Science ®Google Scholar
• Tong Y, Yamaguchi H, Giaime E et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA107, 9879–9884 (2010).
   PubMed Web of Science ®Google Scholar
• Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur. J. Neurosci.24, 3174–3182 (2006).
   PubMed Web of Science ®Google Scholar
• Gao HM, Hong JS, Zhang W, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci.22, 782–790 (2002).
   PubMed Web of Science ®Google Scholar
• Schagger H, Pfeiffer K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. EMBO J.19, 1777–1783 (2000).
   PubMed Web of Science ®Google Scholar
• Stroh A, Anderka O, Pfeiffer K et al. Assembly of respiratory complexes I, III, and IV into NADH oxidase supercomplex stabilizes complex I in Paracoccus denitrificans. J. Biol. Chem.279, 5000–5007 (2004).
   PubMedGoogle Scholar
• Schafer E, Seelert H, Reifschneider NH, Krause F, Dencher NA, Vonck J. Architecture of active mammalian respiratory chain supercomplexes. J. Biol. Chem.281, 15370–15375 (2006).
   PubMed Web of Science ®Google Scholar
• Radad K, Gille G, Rausch WD. Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture. Toxicol. In Vitro22, 68–74 (2008).
   PubMedGoogle Scholar
• Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol.14, 633–643 (1978).
   PubMed Web of Science ®Google Scholar
• Bisaglia M, Tosatto L, Munari F et al. Dopamine quinones interact with α-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun.394, 424–428 (2010).
   PubMedGoogle Scholar
• Hirai H, Pang Z, Bao D et al. Cbln1 is essential for synaptic integrity and plasticity in the cerebellum. Nat. Neurosci.8, 1534–1541 (2005).
   PubMed Web of Science ®Google Scholar
• Kusnoor SV, Muly EC, Morgan JI, Deutch AY. Is the loss of thalamostriatal neurons protective in parkinsonism? Parkinsonism Relat. Disord.15(Suppl. 3), S162–S166 (2009).
   PubMedGoogle Scholar
• Jiang Q, Yan Z, Feng J. Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J. Biol. Chem.281, 29391–29400 (2006).
   PubMedGoogle Scholar
• Bjorklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson’s disease. Neurobiol. Dis.4, 186–200 (1997).
   PubMed Web of Science ®Google Scholar
• Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem.59, 99–106 (1992).
   PubMed Web of Science ®Google Scholar
• Lindholm P, Voutilainen MH, Lauren J et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature448, 73–77 (2007).
   PubMed Web of Science ®Google Scholar
• Hagg T. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo. Exp. Neurol.149, 183–192 (1998).
   PubMed Web of Science ®Google Scholar
• Li Z, Hu Y, Zhu Q, Zhu J. Neurotrophin-3 reduces apoptosis induced by 6-OHDA in PC12 cells through Akt signaling pathway. Int. J. Dev. Neurosci.26, 635–640 (2008).
   PubMedGoogle Scholar
• Kordower JH, Palfi S, Chen EY et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann. Neurol.46, 419–424 (1999).
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol.59, 459–466 (2006).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Burchiel KJ, Comella CL et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology60, 69–73 (2003).
   PubMed Web of Science ®Google Scholar
• Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev.60, 1527–1533 (2008).
   PubMed Web of Science ®Google Scholar
• Mallajosyula JK, Kaur D, Chinta SJ et al. MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS One3, e1616 (2008).
   PubMed Web of Science ®Google Scholar
• Malorni W, Giammarioli AM, Matarrese P et al. Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett.426, 155–159 (1998).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. NY Acad. Sci.939, 320–329 (2001).
   PubMed Web of Science ®Google Scholar
• Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, Magyar K. Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. J. Neural Transm.108, 25–33 (2001).
   PubMedGoogle Scholar
• Zhang X, Zhou JY, Chin MH et al. Region-specific protein abundance changes in the brain of MPTP-induced Parkinson’s disease mouse model. J. Proteome Res.9, 1496–1509 (2010).
   PubMed Web of Science ®Google Scholar
• Collins GG, Youdim MB. Multiple forms of human brain monoamine oxidase: substrate specificities. Biochem. J.117, P43 (1970).
   Google Scholar
• Youdim MB, Holman B. The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline. J. Neural Transm.37, 11–24 (1975).
   PubMedGoogle Scholar
• Westlund KN, Krakower TJ, Kwan SW, Abell CW. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res.612, 221–230 (1993).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br. J. Pharmacol.147(Suppl. 1), S287–S296 (2006).
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron39, 889–909 (2003).
   PubMed Web of Science ®Google Scholar
• Golbe LI. α-synuclein and Parkinson’s disease. Mov. Disord.14, 6–9 (1999).
   PubMed Web of Science ®Google Scholar
• Henze C, Hartmann A, Lescot T, Hirsch EC, Michel PP. Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor. J. Neurochem.95, 1069–1077 (2005).
   PubMedGoogle Scholar
• Duffy HS, John GR, Lee SC, Brosnan CF, Spray DC. Reciprocal regulation of the junctional proteins claudin-1 and connexin43 by interleukin-1β in primary human fetal astrocytes. J. Neurosci.20, RC114 (2000).
   PubMed Web of Science ®Google Scholar
• Wachtel M, Bolliger MF, Ishihara H, Frei K, Bluethmann H, Gloor SM. Down-regulation of occludin expression in astrocytes by tumour necrosis factor (TNF) is mediated via TNF type-1 receptor and nuclear factor-κB activation. J. Neurochem.78, 155–162 (2001).
   PubMed Web of Science ®Google Scholar
• Conti B, Park LC, Calingasan NY et al. Cultures of astrocytes and microglia express interleukin 18. Brain Res. Mol. Brain Res.67, 46–52 (1999).
   PubMedGoogle Scholar
• Sugama S, Cho BP, Baker H, Joh TH, Lucero J, Conti B. Neurons of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat CNS. Brain Res.958, 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Prinz M, Hanisch UK. Murine microglial cells produce and respond to interleukin-18. J. Neurochem.72, 2215–2218 (1999).
   PubMedGoogle Scholar
• Sugama S, Fujita M, Hashimoto M, Conti B. Stress induced morphological microglial activation in the rodent brain: involvement of interleukin-18. Neuroscience146, 1388–1399 (2007).
   PubMed Web of Science ®Google Scholar
• Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Buhrer C, Stahel PF. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci.28, 487–493 (2005).
   PubMed Web of Science ®Google Scholar
• Flynn G, Maru S, Loughlin J, Romero IA, Male D. Regulation of chemokine receptor expression in human microglia and astrocytes. J. Neuroimmunol.136, 84–93 (2003).
   PubMed Web of Science ®Google Scholar
• Dibaj P, Nadrigny F, Steffens H et al. NO mediates microglial response to acute spinal cord injury under ATP control in vivo. Glia58, 1133–1144 (2010).
   PubMedGoogle Scholar
• Caggiano AO, Kraig RP. Eicosanoids and nitric oxide influence induction of reactive gliosis from spreading depression in microglia but not astrocytes. J. Comp. Neurol.369, 93–108 (1996).
   PubMed Web of Science ®Google Scholar
• Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson’s disease. Antioxid. Redox Signal.5, 319–335 (2003).
   PubMed Web of Science ®Google Scholar
• Chen S, Brown IR. Neuronal expression of constitutive heat shock proteins: implications for neurodegenerative diseases. Cell Stress Chaperones12, 51–58 (2007).
   PubMed Web of Science ®Google Scholar
• Acarin L, Paris J, Gonzalez B, Castellano B. Glial expression of small heat shock proteins following an excitotoxic lesion in the immature rat brain. Glia38, 1–14 (2002).
   PubMed Web of Science ®Google Scholar
• Kakimura J, Kitamura Y, Takata K et al. Microglial activation and amyloid-β clearance induced by exogenous heat-shock proteins. FASEB J.16, 601–603 (2002).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Xia Y. Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase. J. Biol. Chem.278, 36953–36958 (2003).
   PubMed Web of Science ®Google Scholar
• Clerget M, Polla BS. Erythrophagocytosis induces heat shock protein synthesis by human monocytes-macrophages. Proc. Natl Acad. Sci. USA87, 1081–1085 (1990).
   PubMed Web of Science ®Google Scholar
• Jeon GS, Park SW, Kim D et al. Glial expression of the 90-kDa heat shock protein (HSP90) and the 94-kDa glucose-regulated protein (GRP94) following an excitotoxic lesion in the mouse hippocampus. Glia48, 250–258 (2004).
   PubMedGoogle Scholar
• Sriram K, Miller DB, O’Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α. J. Neurochem.96, 706–718 (2006).
   PubMed Web of Science ®Google Scholar
• Trujillo JI, Meyers MJ, Anderson DR et al. Novel tetrahydro-β-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg. Med. Chem. Lett.17, 4657–4663 (2007).
   PubMed Web of Science ®Google Scholar
• Wu JP, Wang J, Abeywardane A et al. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors. Bioorg. Med. Chem. Lett.17, 4664–4669 (2007).
   PubMed Web of Science ®Google Scholar
• Palma JP, Kim BS. The scope and activation mechanisms of chemokine gene expression in primary astrocytes following infection with Theiler’s virus. J. Neuroimmunol.149, 121–129 (2004).
   PubMed Web of Science ®Google Scholar
• Ambrosini E, Remoli ME, Giacomini E et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol.64, 706–715 (2005).
   PubMedGoogle Scholar
• Ambrosini E, Aloisi F. Chemokines and glial cells: a complex network in the central nervous system. Neurochem. Res.29, 1017–1038 (2004).
   PubMed Web of Science ®Google Scholar
• Mocco J, Mack WJ, Ducruet AF et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ. Res.99, 209–217 (2006).
   PubMedGoogle Scholar
• Diez M, Abdelmagid N, Harnesk K et al. Identification of gene regions regulating inflammatory microglial response in the rat CNS after nerve injury. J. Neuroimmunol.212, 82–92 (2009).
   PubMedGoogle Scholar
• Gonzalez P, Burgaya F, Acarin L, Peluffo H, Castellano B, Gonzalez B. Interleukin-10 and interleukin-10 receptor-I are upregulated in glial cells after an excitotoxic injury to the postnatal rat brain. J. Neuropathol. Exp. Neurol.68, 391–403 (2009).
   PubMedGoogle Scholar
• Kremlev SG, Palmer C. Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures. J. Neuroimmunol.162, 71–80 (2005).
   PubMed Web of Science ®Google Scholar
• Strle K, Zhou JH, Shen WH, Broussard SR et al. Interleukin-10 in the brain. Crit. Rev. Immunol.21, 427–449 (2001).
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Deprenyl’s effect at slowing progression of Parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta Neurol. Scand. Suppl.136, 79–86 (1991).
   PubMedGoogle Scholar
• Mandel SA, Sagi Y, Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem. Res.32, 1694–1699 (2007).
   PubMed Web of Science ®Google Scholar
• Mandel S, Maor G, Youdim MB. Iron and α-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J. Mol. Neurosci.24, 401–416 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu W, Xie W, Pan T et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J.21, 3835–3844 (2007).
   PubMedGoogle Scholar
• Zhu W, Xie W, Pan T et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J. Neurochem.105, 1970–1978 (2008).
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline; a novel anti-Parkinsonian monoamine oxidase-b inhibitor with neuroprotective activity. Prog. Neurobiol. (2010).
   PubMedGoogle Scholar
• Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MB. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain. J. Neural Transm.116, 1457–1472 (2009).
   PubMedGoogle Scholar
• Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis.25, 35–44 (2007).
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. NY Acad. Sci.1122, 155–168 (2007).
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, Youdim MB. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J. Neural Transm. Suppl. (70), 457–465 (2006).
   PubMedGoogle Scholar
• Ton TG, Heckbert SR, Longstreth WT et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov. Disord.21, 964–969 (2006).
   PubMed Web of Science ®Google Scholar
• Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology74, 995–1002 (2010).
   PubMed Web of Science ®Google Scholar
• Arib O, Rat P, Molimard R, Chait A, Faure P, de Beaurepaire R. Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons. Eur. J. Pharmacol.629, 47–52 (2010).
   PubMed Web of Science ®Google Scholar
• Ruiz-Durantez E, Ruiz-Ortega JA, Pineda J, Ugedo L. Stimulatory effect of harmane and other β-carbolines on locus coeruleus neurons in anaesthetized rats. Neurosci. Lett.308, 197–200 (2001).
   PubMed Web of Science ®Google Scholar
• Abe A, Yamada H. Harmol induces apoptosis by caspase-8 activation independently of Fas/Fas ligand interaction in human lung carcinoma H596 cells. Anticancer Drugs20, 373–381 (2009).
   PubMedGoogle Scholar
• Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H. β-carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem. Toxicol.48, 839–845 (2010).
   PubMed Web of Science ®Google Scholar